Company:
News and Publications
FOR IMMEDIATE RELEASE
For more information contact:
Stephanie Stiles, Director of Marketing
phone: 781.273.5480
sstiles@putassoc.com
John A. Gordon to Speak on Panel
at Harvard Business School
2011 8th Annual Healthcare Conference
Innovation and Risk Mitigation in Drug Development
January 28, 2011 -- Putnam Associates, a Boston-based strategy consulting firm serving the biotechnology and pharmaceutical industries globally, is pleased to announce that John A. Gordon, Partner, will be a panelist at the Harvard Business School 8th Annual Healthcare Conference (www.hbshealthcareclub.org) entitled, “The State of Healthcare Reform: Strategies, Challenges, Success,” held on Saturday, January 29, 2011, 8:00 a.m. — 6:30 p.m. at Harvard Business School.
John Gordon will be a speaker on the biotech and pharmaceutical panel, “Innovation and Risk Mitigation in Drug Development,” taking place at 2:30 pm – 3:30 pm. In addition to Mr. Gordon, panelists include: Tom Hughes, Ph.D., Chief Executive Officer, Zafgen; Ken Kornman, D.D.S., Ph.D., President and Chief Scientific Officer, Interleukin Genetics; Anna Williamson, Ph.D., Senior Manager of Business Development, Genentech; and Vicki Sato, Ph.D., Professor of Management Practice, Harvard Business School (moderator).
Dr. Robert S. Epstein, Chief Medical Officer and President, Medco Health Solutions, Inc. and Angela F. Braly, Chair, President and CEO, WellPoint Inc. will deliver keynote addresses.
A dialogue will occur around these issues:
- What strategies are being adopted to foster innovation in early stage R&D
- How licensing deals are evolving in an environment with constrained capital resources
- Creative approaches that are being taken to shorten development times and increase overall productivity and output of new products
- How companies are dealing with current regulatory and payor challenges
John Gordon has been with Putnam Associates since 1992, and has over 21 years of strategy consulting experience. For more than 18 years, he has counseled senior executives at numerous leading pharmaceutical and biotechnology companies, providing strategic support and recommendations on a wide array of issues, including pricing and reimbursement, health economics and outcomes research, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise Oncology, Immunology, Cardiovascular Disease, and Anti-Infectives. He is published in peer-review literature as a co-author on a study examining the cost effectiveness of a novel immunological agent used in solid organ transplantation. John was moderator and speaker for the biotechnology and pharmaceutical panel at Harvard Business School’s 2010 Annual Healthcare Conference on the topic, “How Will IP Shape Growth?” Prior to joining Putnam, John worked for an economics consulting firm providing expert testimony in matters of corporate and personal litigation. Currently, John serves on the Board of Directors for the National Tay-Sachs & Allied Diseases Association, Inc. John earned a BA in Economics summa cum laude, phi beta kappa from Tufts University and an MBA from Harvard Business School.
Putnam Associates (www.putassoc.com) is a strategy consulting firm headquartered in Boston, founded in 1988, advising the pharmaceutical, biotechnology, diagnostics, and medical device industries on a global basis. Two decades of experience and focus in their industries enable them to create significant value for their clients. Creative and disciplined strategy development processes blend with deep market knowledge for one purpose: to help their clients succeed. The company's partnership includes: Kevin J. Gorman, Managing Partner (BA, Boston College; MBA, Harvard Business School); John A. Gordon, Partner (BA, summa cum laude, Tufts University; MBA, Harvard Business School); Eric C. Auger, Partner (BA, Providence College; MA, Boston University); and Domenick Bertelli, Partner (AB, Harvard University; MBA, MIT Sloan School of Management); Remco op den Kelder, Partner (BA, Fontys University; MSc, University of Strathclyde); Paul Bogorad, Partner (BA, Swarthmore College; MBA, Columbia Business School; Ph.D., Princeton University).